



The  
Patent  
Office

PCT/EP

98/08394

REC'D . 24 FEB 1999
WIPO PCT

INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP9 1RH

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

*Andrew Gervay*

Dated 17 DEC 1998


00.10.00 M

**THIS PAGE BLANK (USPTO)**

Patents Form 1/77

(R)

The  
Patent  
Office



THE PATENT OFFICE

A

19 MAR 1998

RECEIVED BY POST

19MAR98 E346630-1 D02392

P01/7700 25.00 - 9805746.6

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

PB752/GB/RGMS

2. Patent application number

(The Patent Office will fill in this part)

9805746.6

3. Full name, address and postcode of the or of each applicant (underline all surnames)

ALBRIGHT & WILSON UK LIMITED  
210-222 HAGLEY ROAD WEST  
OLDBURY  
WEST MIDLANDS  
B68 0NN

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

ENGLAND

4. Title of the invention

BIOCIDAL COMPOSITIONS AND TREATMENTS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

R G M SAVIDGE  
ALBRIGHT & WILSON UK LIMITED  
PATENTS DEPARTMENT  
PO BOX 3, 210-222 HAGLEY ROAD WEST  
OLDBURY  
WEST MIDLANDS  
B68 0NN

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form.

Do not count copies of the same document

Continuation sheets of this form      NONE

Description      3 PAGES

Claim(s)      NONE

Abstract      NONE

Drawing(s)      NONE

10. If you are also filing any of the following, state how many against each item.

Priority documents      NONE

Translations of priority documents      NONE

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)      NONE

Request for preliminary examination and search (*Patents Form 9/77*)      NONE

Request for substantive examination (*Patents Form 10/77*)      NONE

Any other documents (please specify)      NONE

11. I/We request the grant of a patent on the basis of this application.

Signature

Date 18 March 1998

R G M SAVIDGE - By Power of Attorney

12. Name and daytime telephone number of person to contact in the United Kingdom

MR R G M SAVIDGE  
0121 420 5430

**Warning**

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

**Notes**

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.



PB752/GB

## BIOCIDAL COMPOSITIONS AND TREATMENTS

The present invention relates to synergistic biocidal mixtures containing hydroxymethyl phosphonium biocides which exhibit enhanced biocidal penetration and/or reduced foaming.

GB 2 145 708 describes biocidal uses of tetrakis (hydroxymethyl) phosphonium salts, referred to herein collectively as "THP". GB 2 178 960 describes synergism between THP and surfactant. GB 2 228 680 describes synergism between THP and certain aldehydes.

THP formulations are increasingly widely used as biocides for water treatment in treating cooling water, process water e.g. in pulp and paper manufacture, drilling fluids and other aerobic water systems, as well as in anaerobic systems such as oil field formation water, injection water, produced water and water used in hydrostatic testing. Advantages include rapid and effective bactericidal activity and environmental acceptability. Particularly in systems where slime forming bacteria proliferate (e.g. in aerobic systems such as cooling water) it has been found desirable to use THP formulations containing synergistic amounts of a surfactant according to GB 2 178 960, in order to improve cost effective biocidal action. However such formulations cause foaming problems. Attempts to combine THP with other biocides (e.g. aldehydes), which do not cause foaming, have not been able to provide such effective biocidal action especially against slime forming bacteria, and/or have detracted from the favourable environmental profile of THP.

We have now discovered that combinations of THP with water soluble alkyl glycol ethers provide strongly synergistic biocidal formulations which give excellent penetration of bacterial slime and improved activity against planktonic bacteria without causing excessive foam.

Our invention provides a biocidally synergistic mixture comprising THP and at least one water soluble alkyl glycol ether.



According to a second embodiment the invention provides a method of treating aqueous systems contaminated, or liable to contamination, with bacteria, fungi or algae which comprises applying thereto separately or together a biocidally active amount of the components of a synergistic mixture as aforesaid.

The aqueous system may, for instance, be contaminated with bacterial slime. The invention is of use for treating aerobic systems and also for anaerobic systems.

The THP salt is preferably the sulphate, chloride or phosphate. However any water soluble salt may be used including the nitrate, phosphite, bromide, fluoride, carbonate, acetate, formate, citrate, borate, or silicate. In fact any counter ion which is chemically compatible with the THP cation may be used, the main criteria for selection being economic.

The glycol ether is preferably a water soluble compound of the formula  $\text{HO}[\text{CR}_2\text{CR}_2\text{O}]_n\text{R}'$  where each R is methyl, ethyl or preferably H, provided that the total number of carbon atoms per  $[\text{CR}_2\text{CR}_2\text{O}]$  unit does not exceed 4, more preferably is not more than 3 and most preferably is 2, R' is ethyl or preferably methyl and n is from 1 to 10, especially 1 to 5, typically 1 to 3, preferably 2.

The relative weight proportions of the THP and the glycol ether may range from 1:1000 to 1000:1, preferably 1:200 to 500:1, more preferably 1:100 to 200:1, most preferably 1:50 to 100:1, especially 1:10 to 50:1, more usually 1:5 to 20:1, e.g. 1:1 to 10:1.

The mixture is typically used at a dosage of 1 to 1500ppm by weight THP based on the weight of water to be treated, usually 2 to 500, especially 5 to 250, e.g. 10 to 150.

### Example

An aqueous solution comprising 50% THPS and 2% methyl carbitol (diethylene glycol monomethyl ether) was added to alginate beads infected with sulphate reducing bacteria. When dosed at 250ppm, the solution gave a 100 fold reduction in bacterial counts, compared with a control, after two weeks incubation. A mixture of 50% THP and 2% cationic surfactant was inactive at this concentration.

14-09-01-99

At 500ppm the solution gave a total kill.

The example of the invention also showed superior performance to conventional THP surfactant formulations, to methyl carbitol and to THP alone in reducing both sulphate reducing and planktonic aerobic bacteria.

The example gave less than half the foaming observed using surfactant containing formulations.

The mixture also gives effective control over fungi and algae.

00.10.00 M

**THIS PAGE BLANK (USPTO)**